Brukinsa® (zanubrutinib) – New formulation approval
June 10, 2025 - The FDA approved BeOne Medicines’ Brukinsa (zanubrutinib) tablets, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Waldenström’s macroglobulinemia; relapsed or refractory marginal zone lymphoma who have received at least one anti–CD20-based regimen; chronic lymphocytic leukemia or small lymphocytic lymphoma; relapsed or refractory follicular lymphoma, in combination with obinutuzumab, after two or more lines of systemic therapy.
Top